Our results are particularly important with regard to the clinical translation of FKRP gene therapy, suggesting that early therapeutic interventions are critical for achieving high efficacy and are likely to have the best chance to counteract the deleterious effects of LGMD2I. The gene discussed is FKRP; the disease is autosomal recessive limb-girdle muscular dystrophy type 2I.